Application of electron beam technology in improving sewage water quality: An advance technique

The use of electron beam to disinfect sewage water is gaining importance. The current problem on environmental health in relation to water pollution insists for the safe disposal of sewage water. In general, sewage water comprises of heterogeneous organic based chemicals as well as pathogens. EB (electron beam) treatment of the wastewater was found to be very effective in reducing the pathogens as well as organic load. EB dose of 1.5 kGy was sufficient for complete elimination of total coli forms. The experimental results elucidated that the reduction of biological oxygen demand (BOD) (30.38 and 51.7%) in both inlet and outlet sewage samples. Similarly, reduction of chemical oxygen demand (COD) was observed (37.54 and 52.32%) both sewage samples with respect to increasing of irradiation doses (0.45 to 6 kGy). The present study demonstrated the potential of ionizing radiation for disinfection of sewage and to increase the water quality of the wastewater by decreasing BOD and COD. So, the irradiation sewage water can find its application either in agriculture for irrigation or in industry sector for cooling purpose or in both the sectors.Key words: Disinfection, electron beam accelerator, organic matter, sewage water quality

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Five insights from the Global Burden of Disease Study 2019

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019 provides a rules-based synthesis of the available evidence on levels and trends in health outcomes, a diverse set of risk factors, and health system responses. GBD 2019 covered 204 countries and territories, as well as first administrative level disaggregations for 22 countries, from 1990 to 2019. Because GBD is highly standardised and comprehensive, spanning both fatal and non-fatal outcomes, and uses a mutually exclusive and collectively exhaustive list of hierarchical disease and injury causes, the study provides a powerful basis for detailed and broad insights on global health trends and emerging challenges. GBD 2019 incorporates data from 281 586 sources and provides more than 3.5 billion estimates of health outcome and health system measures of interest for global, national, and subnational policy dialogue. All GBD estimates are publicly available and adhere to the Guidelines on Accurate and Transparent Health Estimate Reporting. From this vast amount of information, five key insights that are important for health, social, and economic development strategies have been distilled. These insights are subject to the many limitations outlined in each of the component GBD capstone papers.Peer reviewe

Congenital Diaphragmatic hernia – a review

Congenital Diaphragmatic hernia (CDH) is a condition characterized by a defect in the diaphragm leading to protrusion of abdominal contents into the thoracic cavity interfering with normal development of the lungs. The defect may range from a small aperture in the posterior muscle rim to complete absence of diaphragm. The pathophysiology of CDH is a combination of lung hypoplasia and immaturity associated with persistent pulmonary hypertension of newborn (PPHN) and cardiac dysfunction. Prenatal assessment of lung to head ratio (LHR) and position of the liver by ultrasound are used to diagnose and predict outcomes. Delivery of infants with CDH is recommended close to term gestation. Immediate management at birth includes bowel decompression, avoidance of mask ventilation and endotracheal tube placement if required. The main focus of management includes gentle ventilation, hemodynamic monitoring and treatment of pulmonary hypertension followed by surgery. Although inhaled nitric oxide is not approved by FDA for the treatment of PPHN induced by CDH, it is commonly used. Extracorporeal membrane oxygenation (ECMO) is typically considered after failure of conventional medical management for infants ≥ 34 weeks’ gestation or with weight >2 kg with CDH and no associated major lethal anomalies. Multiple factors such as prematurity, associated abnormalities, severity of PPHN, type of repair and need for ECMO can affect the survival of an infant with CDH. With advances in the management of CDH, the overall survival has improved and has been reported to be 70-90% in non-ECMO infants and up to 50% in infants who undergo ECMO

Not Available

Not AvailableThe present study was undertaken to assess the growth performance and non-specific immune response of koi carp, Cyprinus carpio exposed to lightemitting diodes (LEDs): blue (450 nm), green (530 nm), yellow (530 nm) and red (630 nm) under long photoperiod (16 h light) for 90 days. White fluorescent light (simulated natural photoperiod, SNP) was used as control. Growth performance of fish was higher (p<0.05) in blue-LED and green-LED exposed groups with significantly higher weight gain percentage, FER and SGR and lower FCR. The concentrations of stress indicators: (cortisol and glucose) were significantly (p<0.05) higher in yellow-LED, red-LED and for control fish group. Total protein, globulin protein, lysozyme activity and respiratory burst activity was significantly higher (p<0.05) in blue-LED and green-LED exposed fish groups whereas, yellow-LED and red-LED exposed fish recorded decline in this parameters after 60 days. The present study recommends that blue and green lights are suitable for better growth and improving the non-specific immune system of koi carpNot Availabl

Not Available

Not AvailableThe present study aimed to evaluate the reproductive performance of Koi carp, Cyprinus carpio exposed to different light spectra using light-emitting diodes, LEDs: blue (peak at 450nm), green (530 nm), yellow (580nm) and red (630nm) within a visible light under long photoperiod (16h, light : 8h, dark) at 0.9 W/m2 light intensity. White fluorescent light (simulated natural photoperiod, SNP) was used as control. The last 30 days of total experimental period (120 days), fishes from all the groups were uniformly exposed to green-LED light to assess the reproductive recovery. The highest levels of both male and female GSI, ova diameter, VTG and sex steroid hormones on 90th day were recorded in green-LED fish group. In case of male the highest concentration of 11-KT hormone was also found in green-LED fish group on 90th day. Yellow and redLED fish groups showed significant lower level of above parameters compared to control (SNP) group. Yellow and redLED fish group showed significant retrieval in gonadal maturation during the recovery period. Therefore, the present study indicates that green light accelerates gonadal maturation of koi carp and use of particular spectrum light likely to facilitates the more-energy efficient aquaculture practices.Not Availabl

A tale of two countries: Comparing disability weights for gambling problems in New Zealand and Australia

Purpose: This study aimed to assess the impact of gambling problems on quality of life. Specifically, we generated disability weight estimates for gambling problems in New Zealand, and compared these results with (i) Australian figures (J Gambl Issues, 10.4309/jgi.v0i36.3978, 2017) and (ii) other health states (Lancet, 10.1016/S0140-6736(12)61680-8, 2013); such as anxiety and alcohol use disorders. Method: The 324 participants (48 experts and 276 general population members) evaluated a series of gambling harm vignettes. The participants rated the decrement to one’s quality of life using Visual Analogue Scale and Time Trade-Off protocols (Br Med Bull, 10.1093/bmb/ldq033, 2010). These evaluations enabled the calculation of disability weights for three categories of gamblers (low-risk, moderate-risk, and problem gamblers). Results: Disability weight estimates for low-risk, moderate-risk, and problem gamblers in NZ were consistently higher than the Australian weights: low (0.18 vs. 0.13), moderate (0.37 vs. 0.29), and problem (0.54 vs. 0.44). The quality of life impact for problem gambling in NZ (0.54) was comparable to that experienced in severe alcohol use disorder (0.55) (Lancet, 10.1016/S0140-6736(12)61680-8, 2013). Conclusions: This study represents one of the first attempts to assess gambling-related harm through a public health perspective. The results of this study are informative for policy-making, resource allocation, and service planning. These estimates now allow for the population-level impact of gambling in NZ to be calculated and tracked over time, which is essential for informing harm-minimisation initiatives. © 2018, Springer International Publishing AG, part of Springer Nature